GSK Sues Apotex to Protect Enlarged Prostate Drug Avodart

Washington Drug Letter
A A
GlaxoSmithKline (GSK) is suing Apotex, saying the generic maker’s proposed version of enlarged prostate drug Avodart would infringe on a GSK patent and should be prohibited from the U.S. market until the patent expires in late 2015.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00